Outcome of epithelial ovarian cancer in women under 40 years of age treated with platinum-based chemotherapy

European Journal of Cancer

Volumn 35, Issue 5, 1999, Pages 727-732

  Lee, C K ^a   Pires De Miranda, M ^a   Ledermann, J A ^a   Ruiz De Elvira, M C ^a   Nelstrop, A E ^b   Lambert, H E ^c   Rustin, G J S ^b   Trask, C W L ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d Southend Hospital   (United Kingdom)

Author keywords

Carboplatin; Epithelial ovarian cancer; Multivariate analysis; Ovarian carcinoma; Platinum chemotherapy; Prognostic factors

Indexed keywords

CARBOPLATIN; CISPLATIN; IPROPLATIN; PLATINUM COMPLEX;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CLINICAL TRIALS, PHASE III; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0345517107     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00011-8     Document Type: Article

References (25)

1. Office of Population Censuses and Surveys. Mortality Statistics: cause (England & Wales) 1991, 1993. OPCS series DH2, No. 18. London, HMSO.
2. McGuire W.P., Hoskins W.J., Brady M.F., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334:1996;1-6.
3. Stuart G., Bertelsen C., Mangioni C., et al. Updated analysis shows a highly significant improved overall survival (OS) for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer: mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish Intergroup trial. Proc. ASCO. 17:1998;1394.
4. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Br Med J 1991, 303, 884-893.
5. Lambert H.E., Rustin G.J.S., Gregory W.M., Nelstrop A.E. A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: a North Thames Ovary Group Study. J. Clin. Oncol. 11:1993;440-448.
6. Lambert H.E., Rustin G.J.S., Gregory W.M., Nelstrop A.E. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma: A North Thames Ovary Group Study. Ann. Oncol. 8:1997;327-333.
7. Trask C., Silverstone A., Ash C.M., et al. A randomized trial of carboplatin versus iproplatin in untreated advanced ovarian cancer. J. Clin. Oncol. 9:1991;1131-1137.
8. Khoo S.K., Battistutta D., Hurst T., Sanderson B.W., Ward B.G., Free K. The prognostic value of clinical, pathologic, and biologic parameters in ovarian cancer. Cancer. 72:1993;531-537.
9. Maker A.P., Baekelamdt M., Tropé C.H., Kristensen G.B. The prognostic significance of residual disease, FIGO substage, histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol. Oncol. 56:1995;175-190.
10. Marsoni S., Torri V., Valsecchi M.G., et al. Prognostic factors in advanced epithelial ovarian cancer. Br. J. Cancer. 65:1990;444-450.
11. Redman J.R., Petroni G.R., Saigo P.E., Geller N.L., Hakes T.B. Prognostic factors in advanced ovarian carcinoma. J. Clin. Oncol. 4:1986;515-523.
12. Omura G.A., Brady M.F., Homesley H.D., et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J. Clin. Oncol. 9:1991;1138-1150.
13. Swenerton K.D., Hislop T.G., Spinelli J., LeRiche J.C., Yang N., Boyes D.A. Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet. Gynecol. 65:1986;264-269.
14. Thigpen T., Brady M.F., Omura G.A., et al. Age as a prognostic factor in ovarian carcinoma. Cancer. 71:1993;606-614.
15. Plaxe S.C., Braly P.S., Fredo J.L., McClay E., Kirmani S., Howell S.B. Profiles of women age 30-39 and age less than 30 with epithelial ovarian cancer. Obstet. Gynecol. 81:1993;651-654.
16. Yancik R. Ovarian cancer: age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer. 71:1993;517-523.
17. Gloeckler Ries L.A. Ovarian cancer. Cancer. 71:1993;524-529.
18. Massi D., Susini T., Savino L., Boddi V., Amunni G., Colafranceschi M. Epithelial ovarian tumors in the reproductive age group: age is not an independent prognostic factor. Cancer. 77:1996;1131-1136.
19. Smedley H., Sikora K. Age as a prognostic factor in epithelial ovarian carcinoma. Br. J. Obstet. Gynecol. 92:1985;839-842.
20. Christensen E. Multivariate survival analysis using Cox's regression model. Hepatology. 7:1987;1346-1358.
21. Bjorkholm E., Pettersson F., Einhorn N., Krebs I., Nilsson B., Tjernberg B. Long-term follow-up and prognostic factors in ovarian carcinoma. The Radiumhemmet series 1958 to 1973. Acta. Radiol. Oncol. 21:1982;413-419.
22. Gershenson D.M., Mitchell M.F., Atkinson N., et al. Age contrasts in patients with advanced epithelial ovarian cancer. The M.D. Anderson Cancer Center experience. Cancer. 71:(2 Suppl):1993;638-643.
23. Rubin S.C., Benjamin I., Behbakht K., et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N. Engl. J. Med. 335:1996;1413-1416.
24. Berchuck A., Carney M. Human ovarian cancer of the surface epithelium. Biochem. Pharmacol. 54:1997;541-544.
25. Schildkraut J.M., Bastos E., Berchuck A. Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. J. Natl. Cancer Inst. 89:1997;932-938.